Pregabalin open-label, multicenter add-on trial following a 4-day double-blind transition period to determine long-term safety and efficacy in patients with partial seizures

Trial Profile

Pregabalin open-label, multicenter add-on trial following a 4-day double-blind transition period to determine long-term safety and efficacy in patients with partial seizures

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2006

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top